{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:41:21Z","timestamp":1789530081478,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>microRNAs (miRNAs) play pivotal roles in polycystic ovary syndrome (PCOS), an endocrine and metabolic disorder that commonly occurs in women of childbearing age. This paper aimed to measure miR-222-3p expression in sera of PCOS patients and to explore its clinical value on PCOS diagnosis and prediction of diabetic and cardiovascular complications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Totally 111 PCOS patients and 94 healthy people were recruited and assigned to the overweight (ow) group and non-overweight (non-ow) group, followed by determination of serum miR-222-3p expression. The diagnostic efficiency of miR-222-3p on PCOS ow and non-ow patients was analyzed. Correlations between miR-222-3p and glycolipid metabolic indicators and diabetic and cardiovascular complications in PCOS were analyzed. The downstream target of miR-222-3p was predicted and their binding relationship was verified. The correlation between PGC-1\u03b1 and miR-222-3p was analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>miR-222-3p was highly-expressed in PCOS patients (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), in especially PCOS ow patients. The area under the curve (AUC) of miR-222-3p diagnosing PCOS non-ow patients was 0.9474 and cut-off value was 1.290 (89.06% sensitivity, 98.11% specificity), indicating that non-ow people with serum miR-222-3p\u2009&gt;\u20091.290 could basically be diagnosed with PCOS. AUC of miR-222-3p diagnosing PCOS ow patients was 0.9647 and cut-off value was 2.425 (85.11% sensitivity, 100% specificity), suggesting that ow people with serum miR-222-3p\u2009&gt;\u20092.425 could basically be diagnosed with PCOS. miR-222-3p was positively-correlated with fasting plasma glucose (FPG), fasting insulin (FINS), homeostatic model assessment\u2013insulin resistance (HOMA-IR), and low-density lipoprotein cholesterol (LDL-C) and negatively-correlated with high-density lipoprotein cholesterol (HDL-C). miR-222-3p was independently-correlated with diabetic and cardiovascular complications in PCOS (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). High expression of miR-222-3p predicted high risks of diabetic and cardiovascular complications in PCOS. miR-222-3p targeted PGC-1\u03b1 and was negatively-correlated with PGC-1\u03b1 (r\u2009=\u2009\u2212\u00a00.2851, <jats:italic>p<\/jats:italic>\u2009=\u20090.0224; r\u2009=\u2009\u2212\u00a00.3151, <jats:italic>p<\/jats:italic>\u2009=\u20090.0310).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>High expression of miR-222-3p assisted PCOS diagnosis and predicted increased risks of diabetic and cardiovascular complications. miR-222-3p targeted PGC-1\u03b1 and was negatively-correlated with PGC-1\u03b1.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12905-022-01912-w","type":"journal-article","created":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T09:07:08Z","timestamp":1664615228000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Correlation study on serum miR-222-3p and glucose and lipid metabolism in patients with polycystic ovary syndrome"],"prefix":"10.1186","volume":"22","author":[{"given":"Qin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanxiang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,1]]},"reference":[{"issue":"4","key":"1912_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrendo.2010.217","volume":"7","author":"MO Goodarzi","year":"2011","unstructured":"Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7(4):219\u201331.","journal-title":"Nat Rev Endocrinol"},{"key":"1912_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000341673","volume":"40","author":"S Livadas","year":"2013","unstructured":"Livadas S, Diamanti-Kandarakis E. Polycystic ovary syndrome: definitions, phenotypes and diagnostic approach. Front Horm Res. 2013;40:1\u201321.","journal-title":"Front Horm Res"},{"issue":"6","key":"1912_CR3","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1542\/peds.2015-1430","volume":"136","author":"RL Rosenfield","year":"2015","unstructured":"Rosenfield RL. The diagnosis of polycystic ovary syndrome in adolescents. Pediatrics. 2015;136(6):1154\u201365.","journal-title":"Pediatrics"},{"issue":"1","key":"1912_CR4","first-page":"45","volume":"74","author":"MN D'Alterio","year":"2022","unstructured":"D\u2019Alterio MN, Sigilli M, Succu AG, Ghisu V, Lagana AS, Sorrentino F, Nappi L, Tinelli R, Angioni S. Pregnancy outcomes in women with polycystic ovarian syndrome. Minerva Obstet Gynecol. 2022;74(1):45\u201359.","journal-title":"Minerva Obstet Gynecol"},{"issue":"6","key":"1912_CR5","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s11655-017-2810-4","volume":"23","author":"DW Ye","year":"2017","unstructured":"Ye DW, Rong XL, Xu AM, Guo J. Liver-adipose tissue crosstalk: A key player in the pathogenesis of glucolipid metabolic disease. Chin J Integr Med. 2017;23(6):410\u20134.","journal-title":"Chin J Integr Med"},{"issue":"5","key":"1912_CR6","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1093\/humrep\/deq028","volume":"25","author":"X Chen","year":"2010","unstructured":"Chen X, Ni R, Mo Y, Li L, Yang D. Appropriate BMI levels for PCOS patients in Southern China. Hum Reprod. 2010;25(5):1295\u2013302.","journal-title":"Hum Reprod"},{"issue":"7","key":"1912_CR7","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.molmed.2006.05.006","volume":"12","author":"E Diamanti-Kandarakis","year":"2006","unstructured":"Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med. 2006;12(7):324\u201332.","journal-title":"Trends Mol Med"},{"issue":"6","key":"1912_CR8","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/GCO.0000000000000410","volume":"29","author":"D Glintborg","year":"2017","unstructured":"Glintborg D, Andersen M. Medical comorbidity in polycystic ovary syndrome with special focus on cardiometabolic, autoimmune, hepatic and cancer diseases: an updated review. Curr Opin Obstet Gynecol. 2017;29(6):390\u20136.","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"7","key":"1912_CR9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.tem.2007.08.001","volume":"18","author":"HJ Teede","year":"2007","unstructured":"Teede HJ, Hutchison SK, Zoungas S. The management of insulin resistance in polycystic ovary syndrome. Trends Endocrinol Metab. 2007;18(7):273\u20139.","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"1912_CR10","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.jaci.2017.08.034","volume":"141","author":"TX Lu","year":"2018","unstructured":"Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018;141(4):1202\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"1912_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.mce.2015.01.030","volume":"404","author":"B Xu","year":"2015","unstructured":"Xu B, Zhang YW, Tong XH, Liu YS. Characterization of microRNA profile in human cumulus granulosa cells: identification of microRNAs that regulate Notch signaling and are associated with PCOS. Mol Cell Endocrinol. 2015;404:26\u201336.","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"1912_CR12","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1159\/000358698","volume":"33","author":"W Long","year":"2014","unstructured":"Long W, Zhao C, Ji C, Ding H, Cui Y, Guo X, Shen R, Liu J. Characterization of serum microRNAs profile of PCOS and identification of novel non-invasive biomarkers. Cell Physiol Biochem. 2014;33(5):1304\u201315.","journal-title":"Cell Physiol Biochem"},{"issue":"11","key":"1912_CR13","doi-asserted-by":"publisher","first-page":"E1835","DOI":"10.1210\/jc.2013-2218","volume":"98","author":"M Murri","year":"2013","unstructured":"Murri M, Insenser M, Fernandez-Duran E, San-Millan JL, Escobar-Morreale HF. Effects of polycystic ovary syndrome (PCOS), sex hormones, and obesity on circulating miRNA-21, miRNA-27b, miRNA-103, and miRNA-155 expression. J Clin Endocrinol Metab. 2013;98(11):E1835-1844.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1912_CR14","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.prp.2019.01.038","volume":"215","author":"X Huang","year":"2019","unstructured":"Huang X, She L, Luo X, Huang S, Wu J. MiR-222 promotes the progression of polycystic ovary syndrome by targeting p27 Kip1. Pathol Res Pract. 2019;215(5):918\u201323.","journal-title":"Pathol Res Pract"},{"issue":"22","key":"1912_CR15","first-page":"22719","volume":"12","author":"D Li","year":"2020","unstructured":"Li D, Song H, Shuo L, Wang L, Xie P, Li W, Liu J, Tong Y, Zhang CY, Jiang X, et al. Gonadal white adipose tissue-derived exosomal MiR-222 promotes obesity-associated insulin resistance. Aging (Albany NY). 2020;12(22):22719\u201343.","journal-title":"Aging (Albany NY)"},{"issue":"4","key":"1912_CR16","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.hbpd.2019.05.002","volume":"18","author":"JJ Wang","year":"2019","unstructured":"Wang JJ, Zhang YT, Tseng YJ, Zhang J. miR-222 targets ACOX1, promotes triglyceride accumulation in hepatocytes. Hepatobiliary Pancreat Dis Int. 2019;18(4):360\u20135.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"2","key":"1912_CR17","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.atherosclerosis.2015.06.031","volume":"241","author":"Y Xue","year":"2015","unstructured":"Xue Y, Wei Z, Ding H, Wang Q, Zhou Z, Zheng S, Zhang Y, Hou D, Liu Y, Zen K, et al. MicroRNA-19b\/221\/222 induces endothelial cell dysfunction via suppression of PGC-1alpha in the progression of atherosclerosis. Atherosclerosis. 2015;241(2):671\u201381.","journal-title":"Atherosclerosis"},{"issue":"3","key":"1912_CR18","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s13577-019-00252-6","volume":"32","author":"Y Liu","year":"2019","unstructured":"Liu Y, Zhai J, Chen J, Wang X, Wen T. PGC-1alpha protects against oxidized low-density lipoprotein and luteinizing hormone-induced granulosa cells injury through ROS-p38 pathway. Hum Cell. 2019;32(3):285\u201396.","journal-title":"Hum Cell"},{"issue":"6","key":"1912_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002466","volume":"3","author":"V Skov","year":"2008","unstructured":"Skov V, Glintborg D, Knudsen S, Tan Q, Jensen T, Kruse TA, Beck-Nielsen H, Hojlund K. Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome. PLoS ONE. 2008;3(6): e2466.","journal-title":"PLoS ONE"},{"issue":"5","key":"1912_CR20","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/s41366-019-0508-8","volume":"44","author":"L Li","year":"2020","unstructured":"Li L, Yao Y, Zhao J, Cao J, Ma H. Dehydroepiandrosterone protects against hepatic glycolipid metabolic disorder and insulin resistance induced by high fat via activation of AMPK-PGC-1alpha-NRF-1 and IRS1-AKT-GLUT2 signaling pathways. Int J Obes (Lond). 2020;44(5):1075\u201386.","journal-title":"Int J Obes (Lond)"},{"issue":"3","key":"1912_CR21","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1210\/jc.2005-2501","volume":"91","author":"S Franks","year":"2006","unstructured":"Franks S. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab. 2006;91(3):786\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7 Suppl","key":"1912_CR22","first-page":"s176","volume":"22","author":"CM Apovian","year":"2016","unstructured":"Apovian CM. Obesity: definition, comorbidities, causes, and burden. Am J Manag Care. 2016;22(7 Suppl):s176-185.","journal-title":"Am J Manag Care"},{"issue":"2","key":"1912_CR23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/AOG.0000000000002698","volume":"132","author":"R Azziz","year":"2018","unstructured":"Azziz R. Polycystic ovary syndrome. Obstet Gynecol. 2018;132(2):321\u201336.","journal-title":"Obstet Gynecol"},{"key":"1912_CR24","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.cca.2019.09.010","volume":"499","author":"JL Zhu","year":"2019","unstructured":"Zhu JL, Chen Z, Feng WJ, Long SL, Mo ZC. Sex hormone-binding globulin and polycystic ovary syndrome. Clin Chim Acta. 2019;499:142\u20138.","journal-title":"Clin Chim Acta"},{"issue":"3","key":"1912_CR25","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1039\/C9FO00861F","volume":"11","author":"M Gan","year":"2020","unstructured":"Gan M, Shen L, Wang S, Guo Z, Zheng T, Tan Y, Fan Y, Liu L, Chen L, Jiang A, et al. Genistein inhibits high fat diet-induced obesity through miR-222 by targeting BTG2 and adipor1. Food Funct. 2020;11(3):2418\u201326.","journal-title":"Food Funct"},{"issue":"5","key":"1912_CR26","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.tjog.2017.08.014","volume":"56","author":"AH Hosseini","year":"2017","unstructured":"Hosseini AH, Kohan L, Aledavood A, Rostami S. Association of miR-146a rs2910164 and miR-222 rs2858060 polymorphisms with the risk of polycystic ovary syndrome in Iranian women: a case-control study. Taiwan J Obstet Gynecol. 2017;56(5):652\u20136.","journal-title":"Taiwan J Obstet Gynecol"},{"key":"1912_CR27","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.omtn.2020.07.014","volume":"22","author":"H Ye","year":"2020","unstructured":"Ye H, Liu XJ, Hui Y, Liang YH, Li CH, Wan Q. Downregulation of MicroRNA-222 Reduces Insulin Resistance in Rats with PCOS by Inhibiting Activation of the MAPK\/ERK Pathway via Pten. Mol Ther Nucleic Acids. 2020;22:733\u201341.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"1912_CR28","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s11033-018-4547-3","volume":"46","author":"A Gorur","year":"2019","unstructured":"Gorur A, Celik A, Yildirim DD, Gundes A, Tamer L. Investigation of possible effects of microRNAs involved in regulation of lipid metabolism in the pathogenesis of atherosclerosis. Mol Biol Rep. 2019;46(1):909\u201320.","journal-title":"Mol Biol Rep"},{"issue":"1","key":"1912_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ecl.2013.10.003","volume":"43","author":"A Nandi","year":"2014","unstructured":"Nandi A, Chen Z, Patel R, Poretsky L. Polycystic ovary syndrome. Endocrinol Metab Clin North Am. 2014;43(1):123\u201347.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"6","key":"1912_CR30","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.jpag.2016.07.001","volume":"29","author":"M Rezaee","year":"2016","unstructured":"Rezaee M, Asadi N, Pouralborz Y, Ghodrat M, Habibi S. A review on glycosylated hemoglobin in polycystic ovary syndrome. J Pediatr Adolesc Gynecol. 2016;29(6):562\u20136.","journal-title":"J Pediatr Adolesc Gynecol"},{"issue":"10","key":"1912_CR31","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1080\/17512433.2018.1519391","volume":"11","author":"U Ravnskov","year":"2018","unstructured":"Ravnskov U, de Lorgeril M, Diamond DM, Hama R, Hamazaki T, Hammarskjold B, Hynes N, Kendrick M, Langsjoen PH, Mascitelli L, et al. LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature. Expert Rev Clin Pharmacol. 2018;11(10):959\u201370.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1912_CR32","doi-asserted-by":"publisher","first-page":"4962426","DOI":"10.1155\/2017\/4962426","volume":"2017","author":"S Ding","year":"2017","unstructured":"Ding S, Huang H, Xu Y, Zhu H, Zhong C. MiR-222 in cardiovascular diseases: physiology and pathology. Biomed Res Int. 2017;2017:4962426.","journal-title":"Biomed Res Int"},{"key":"1912_CR33","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.2147\/DMSO.S263883","volume":"13","author":"S Sadeghzadeh","year":"2020","unstructured":"Sadeghzadeh S, DehghaniAshkezari M, Seifati SM, VahidiMehrjardi MY, DehghanTezerjani M, Sadeghzadeh S, Ladan SAB. Circulating miR-15a and miR-222 as potential biomarkers of Type 2 diabetes. Diabetes Metab Syndr Obes. 2020;13:3461\u20139.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"1912_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.658112","volume":"9","author":"L Sun","year":"2021","unstructured":"Sun L, Tian H, Xue S, Ye H, Xue X, Wang R, Liu Y, Zhang C, Chen Q, Gao S. Circadian clock genes REV-ERBs inhibits granulosa cells apoptosis by regulating mitochondrial biogenesis and autophagy in polycystic ovary syndrome. Front Cell Dev Biol. 2021;9: 658112.","journal-title":"Front Cell Dev Biol"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-022-01912-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-022-01912-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-022-01912-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T09:07:33Z","timestamp":1664615253000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-022-01912-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1912"],"URL":"https:\/\/doi.org\/10.1186\/s12905-022-01912-w","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,1]]},"assertion":[{"value":"23 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was initiated under the approval of the Ethics Committee of The First Affiliated Hospital of Gannan Medical University (Approval Number: LLSC-2021120202). Each participant was informed of this study and provided written informed consent. All methods were performed following the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"398"}}